Innate Pharma
Innate Pharma
-1,28 %
5,785 EUR
-0,08
Kurs
5,785
Hög
5,855
Förändring
-1,28 %
Låg
5,780
Uppdaterad
09:03:59
Öppen
5,855
Factsheet for Innate Pharma
Company Profile
Description
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results primarily from payments received in relation to research, collaboration and licensing agreements signed with pharmaceutical companies.
Key Stats
Website: https://www.innate-pharma.com
Headquarter country: France
Employees: 84
Market Cap (at close 15-07-2019): EUR 369M
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 48,30
Forward Price/Earnings 12,80
Price/Free Cash Flow 2,90 3,60
Return on Assets 0,90 -18,00 4,30 -3,40 -26,80
Return on Equity 2,40 -56,20 16,00 -9,10 -34,20
Return on Invested Capital 2,40 -52,70 15,30 -8,50 -31,40
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 79,89 32,63 56,16 17,91 0,91
Gross Profit 0,03 0,06 0,02 -0,01
Gross Margin % 100,00% 100,00% 100,00% -1 232,64%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 10,00 -44,00 16,00 -4,00 -17,00
Net income 3,00 -48,00 13,00 -7,00 -20,00
Basic Earnings Per Share 0,05 -0,89 0,23 -0,13 -0,39
Operating Income 0,01 -0,04 0,01 -0,01 -0,02
Operating Margin % 6,44% -122,52% 13,48% -60,16% -2 198,57%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -33,00 -48,00 -37,00 208,00 -18,00
Capital Expenditures -1,00 -6,00 -9,00 -7,00 -2,00
Free Cash Flow -34,00 -54,00 -46,00 201,00 -20,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 319,64 137,52 230,08 252,13 79,31 49,35
Long Term Assets 131,57 117,50 51,50 53,83 11,38 6,53
Total Assets 451,22 255,02 281,58 305,96 90,69 55,88
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 196,74 73,91 76,44 60,16 10,78 9,28
Long Term Liabilities 118,97 173,73
Total Liabilities 195,41 233,89
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -134,79 -151,98 -103,60 -116,23 -109,53 -89,96
Treasury Stock
Total Stockholder Equity 167,24 85,96 86,17 72,07 74,63 40,29
Net Tangible Assets 82,71 39,76 77,09 62,34 69,26 40,29